A multi-institutional database to stimulate new research protocols, identify potential need for future expansion of the network to incorporate additional patient populations, and provide a descriptive understanding of children with hydrocephalus cared for within the network.
The study uses a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing, targeted panel profile, and RNA-Seq to test the efficacy of such an approach in children with high-grade gliomas.
A phase I trial studying the side effects of nivolumab before and after surgery in treating children and young adults with high-grade glioma that has come back or is increasing in scope or severity.
This trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia improves outcomes.
A study to determine the response of younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment.
A multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years old with newly diagnosed medulloblastoma.
The Children's Oncology Group maintains a childhood cancer registry of infants, children, adolescents, and young adults with cancer called Project:EveryChild, which supports current and future therapeutic clinical trials and the discovery efforts that will lead to more effective therapies, prevention, earlier detection and reductions in early and late effects of treatment.
The objective of this study is to ensure that patients with localized central nervous system non-germinomatous germ cell tumors treated with induction chemotherapy followed by response evaluation and whole ventricular + spinal canal irradiation maintain excellent 2-year progression free survival.
The study hypothesizes that use of cabozantinib in pediatric patients with ultra-high-risk solid tumors with minimal disease burden can prevent or slow recurrent tumor formation and significantly extend the period of disease control.
This study aims to demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival is non-inferior compared with treatment with carboplatin/vincristine in previously untreated low-grad glioma.
A phase III study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment.